scholarly journals Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence- free survival in patients with prostate cancer

2014 ◽  
pp. 137 ◽  
Author(s):  
Weide Zhong ◽  
Guo-qiang Qin ◽  
Hui-chan He ◽  
Zhao-dong Han ◽  
Yu-xiang Liang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Combined Overexpression

scholarly journals High levels of DEPDC1B predict shorter biochemical recurrence‑free survival of patients with prostate cancer

2017 ◽  
Author(s):  
Shoumin Bai ◽  
Ting Chen ◽  
Tao Du ◽  
Xianju Chen ◽  
Yiming Lai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Recurrence Free Survival ◽  
Free Survival

Biochemical Recurrence–free Survival After Robotic-assisted Laparoscopic vs Open Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer

Urology ◽  
2014 ◽  
Vol 83 (6) ◽  
pp. 1309-1315 ◽  
Author(s):  
Chad R. Ritch ◽  
Chaochen You ◽  
Alexandra T. May ◽  
S. Duke Herrell ◽  
Peter E. Clark ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Biochemical Recurrence ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Robotic Assisted ◽  
High Risk Prostate Cancer ◽  
Open Radical Prostatectomy ◽  
Risk Prostate Cancer

scholarly journals Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival

2008 ◽  
Vol 14 (3) ◽  
pp. 758-763 ◽  
Author(s):  
Joseph R. Sterbis ◽  
Chunling Gao ◽  
Bungo Furusato ◽  
Yongmei Chen ◽  
Syed Shaheduzzaman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Cancer Tissues

Impact of testosterone replacement therapy after radiation therapy on prostate cancer outcomes.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 99-99
Author(s):  
Reith Sarkar ◽  
J Kellogg Parsons ◽  
John Paul Einck ◽  
Arno James Mundt ◽  
A. Karim Kader ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Biochemical Recurrence ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Treatment Groups

99 Background: Currently there is little data to guide the use of testosterone replacement therapy in prostate cancer patients who have received radiation therapy (RT). We sought to evaluate the impact of post-RT testosterone replacement on prostate cancer outcomes in a large national cohort. Methods: We conducted a population-based cohort study using the Veterans Affairs Informatics and Computing Infrastructure. We identified node-negative and non-metastatic prostate cancer patients diagnosed between 2001-2015 treated with RT. We excluded patients for missing covariate and follow-up data. Receipt of testosterone was coded as a time-dependent covariate. Other covariates included: age, Charlson Comorbidity index, diagnosis year, body mass index, race, PSA, clinical T/N/M stage, Gleason score, and receipt of hormone therapy. We evaluated prostate cancer-specific survival, overall survival, and biochemical recurrence free survival using multivariable Cox regression. Results: Our cohort included 41,544 patients, of whom 544 (1.3%) received testosterone replacement after RT. There were no differences in Charlson comorbidity, clinical T stage, median pre-treatment PSA or Gleason score between treatment groups. Testosterone patients were more likely to be of younger age, non-black, have a lower median post-treatment PSA nadir (0.1 vs. 0.2; p < 0.001), have higher BMI, and have used hormone therapy (46.7% vs 40.3%; p = 0.003). Median duration of ADT usage was equivalent between treatment groups (testosterone: 185 days vs. non-testosterone: 186 days, p = 0.77). The median time from RT to TRT was 3.52 years. After controlling for differences in covariates between treatment groups, we found no difference in prostate cancer specific mortality (HR 1.02; 95% CI 0.62-1.67; p = 0.95), overall survival (HR 1.02; 95% CI 0.84-1.24; p = 0.86), non-cancer mortality (HR 1.02; 95% CI 0.82-1.27; p = 0.86) biochemical recurrence free survival (HR 1.07; 95% CI 0.90-1.28; p = 0.45). Conclusions: Our results suggest that testosterone replacement is safe in prostate cancer patients who have received RT. Prospective data are required to confirm the safety of post-RT testosterone replacement.

Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer

2013 ◽  
Vol 31 (4) ◽  
pp. 468-474 ◽  
Author(s):  
Goran Benko ◽  
Borislav Spajić ◽  
Božo Krušlin ◽  
Davor Tomas
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Localized Prostate Cancer ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Epcam Expression

scholarly journals Association of doublecortin-like kinase 1 with tumor aggressiveness and poor biochemical recurrence-free survival in prostate cancer

2018 ◽  
Vol Volume 11 ◽  
pp. 1077-1086 ◽  
Author(s):  
Donggen Jiang ◽  
Chutian Xiao ◽  
Tuzeng Xian ◽  
Liantao Wang ◽  
Yunhua Mao ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Recurrence Free Survival ◽  
Tumor Aggressiveness ◽  
Free Survival
Sign in / Sign up

Export Citation Format

Share Document